Research at UHN
@uhnresearch.ca
Research news from Canada's largest research hospital.
🔗 uhnresearch.ca
🔗 uhnresearch.ca
Pinned
Research at UHN
@uhnresearch.ca
· Nov 10
Driving Discovery. Delivering Impact.🎯
A story of science that’s bold, transformative, and collaborative.
This #WorldScienceDay, explore our annual research report and discover how @uhn.ca is building #AHealthierWorld.
➡️: www.uhnresearch.ca/Research-Rep...
#RR25 #DiscoveryToImpact
A story of science that’s bold, transformative, and collaborative.
This #WorldScienceDay, explore our annual research report and discover how @uhn.ca is building #AHealthierWorld.
➡️: www.uhnresearch.ca/Research-Rep...
#RR25 #DiscoveryToImpact
Researchers at @uhn.ca’s @pmresearch-uhn.bsky.social have found that inactivation of the TET2 gene can improve #cancer immunotherapy response—opening the door for more personalized treatment strategies.
🔗 Read more: www.uhnresearch.ca/news/linking...
--
@uoftmedicine.bsky.social
🔗 Read more: www.uhnresearch.ca/news/linking...
--
@uoftmedicine.bsky.social
January 6, 2026 at 8:16 PM
Researchers at @uhn.ca’s @pmresearch-uhn.bsky.social have found that inactivation of the TET2 gene can improve #cancer immunotherapy response—opening the door for more personalized treatment strategies.
🔗 Read more: www.uhnresearch.ca/news/linking...
--
@uoftmedicine.bsky.social
🔗 Read more: www.uhnresearch.ca/news/linking...
--
@uoftmedicine.bsky.social
A collaborative @kbi-uhn.bsky.social & @uoftmedicine.bsky.social team has identified a biomarker linked to the inflammation that drives progressive #MultipleSclerosis. This is a step toward more precise diagnosis & treatment.
🔗️https://www.uhnresearch.ca/news/new-clues-multiple-sclerosis
🔗️https://www.uhnresearch.ca/news/new-clues-multiple-sclerosis
January 2, 2026 at 4:44 PM
A collaborative @kbi-uhn.bsky.social & @uoftmedicine.bsky.social team has identified a biomarker linked to the inflammation that drives progressive #MultipleSclerosis. This is a step toward more precise diagnosis & treatment.
🔗️https://www.uhnresearch.ca/news/new-clues-multiple-sclerosis
🔗️https://www.uhnresearch.ca/news/new-clues-multiple-sclerosis
(3/3) Dr. Allison McGeer, Clinician Investigator at UHN & Senior Clinician Scientist at @sinaihealth.bsky.social, has been appointed as a Member of the Order for her work in #epidemiology, which has shaped national and global strategies for preventing infections.
December 31, 2025 at 6:25 PM
(3/3) Dr. Allison McGeer, Clinician Investigator at UHN & Senior Clinician Scientist at @sinaihealth.bsky.social, has been appointed as a Member of the Order for her work in #epidemiology, which has shaped national and global strategies for preventing infections.
(2/3) Dr. Shaf Keshavjee, Senior Scientist & Chief of Innovation at UHN, has been promoted from Officer to Companion of the Order. He has made significant contributions to #transplantation through the development of Ex Vivo Lung Perfusion & his research in lung preservation for transplants.
December 31, 2025 at 6:25 PM
(2/3) Dr. Shaf Keshavjee, Senior Scientist & Chief of Innovation at UHN, has been promoted from Officer to Companion of the Order. He has made significant contributions to #transplantation through the development of Ex Vivo Lung Perfusion & his research in lung preservation for transplants.
(1/3) 🎉 Congratulations to @uhn.ca researchers Drs. Shaf Keshavjee and Allison McGeer on their appointments to the Order of Canada! Their work has advanced research in #transplantation and #InfectiousDisease worldwide.
🔗 Read the full press release: gg.ca/en/media/new...
🔗 Read the full press release: gg.ca/en/media/new...
December 31, 2025 at 6:25 PM
(1/3) 🎉 Congratulations to @uhn.ca researchers Drs. Shaf Keshavjee and Allison McGeer on their appointments to the Order of Canada! Their work has advanced research in #transplantation and #InfectiousDisease worldwide.
🔗 Read the full press release: gg.ca/en/media/new...
🔗 Read the full press release: gg.ca/en/media/new...
As 2025 comes to a close, we look forward to a new year full of opportunities to continue creating #AHealthierWorld.
Happy holidays from @uhnresearch.ca!
Happy holidays from @uhnresearch.ca!
December 22, 2025 at 4:41 PM
As 2025 comes to a close, we look forward to a new year full of opportunities to continue creating #AHealthierWorld.
Happy holidays from @uhnresearch.ca!
Happy holidays from @uhnresearch.ca!
A @uhn.ca study reveals gaps in #HepatitisC care for pregnant people.
Fewer than 10% of patients began treatment within 5 years of diagnosis, and many had multiple pregnancies before treatment. This highlights the need for stronger linkage-to-care.
🔗 Read more: doi.org/10.1093/cid/...
Fewer than 10% of patients began treatment within 5 years of diagnosis, and many had multiple pregnancies before treatment. This highlights the need for stronger linkage-to-care.
🔗 Read more: doi.org/10.1093/cid/...
December 18, 2025 at 8:02 PM
A @uhn.ca study reveals gaps in #HepatitisC care for pregnant people.
Fewer than 10% of patients began treatment within 5 years of diagnosis, and many had multiple pregnancies before treatment. This highlights the need for stronger linkage-to-care.
🔗 Read more: doi.org/10.1093/cid/...
Fewer than 10% of patients began treatment within 5 years of diagnosis, and many had multiple pregnancies before treatment. This highlights the need for stronger linkage-to-care.
🔗 Read more: doi.org/10.1093/cid/...
December 18, 2025 at 4:18 PM
New publication alert!
@uhn.ca's Dr. Viswanathan leads international experts on #MesenchymalStromalCells mechanism of action. Identifying research gaps and future directions will help boost the safety and efficacy of MSCs for conditions like #Arthritis.
🔗: www.isct-cytotherapy.org/article/S146...
@uhn.ca's Dr. Viswanathan leads international experts on #MesenchymalStromalCells mechanism of action. Identifying research gaps and future directions will help boost the safety and efficacy of MSCs for conditions like #Arthritis.
🔗: www.isct-cytotherapy.org/article/S146...
Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions
The in vivo fate of mesenchymal stromal cells (MSCs), including their clearance, interaction
with host tissues, and persistence, remains incompletely understood following systemic
or local clinical ad...
www.isct-cytotherapy.org
December 18, 2025 at 4:18 PM
New publication alert!
@uhn.ca's Dr. Viswanathan leads international experts on #MesenchymalStromalCells mechanism of action. Identifying research gaps and future directions will help boost the safety and efficacy of MSCs for conditions like #Arthritis.
🔗: www.isct-cytotherapy.org/article/S146...
@uhn.ca's Dr. Viswanathan leads international experts on #MesenchymalStromalCells mechanism of action. Identifying research gaps and future directions will help boost the safety and efficacy of MSCs for conditions like #Arthritis.
🔗: www.isct-cytotherapy.org/article/S146...
🎉 Congratulations to @uhn.ca’s Dr. Sonya MacParland on receiving funding through ERDERA’s Joint Transnational Call 2025!
This patient-partnered project advances research in primary sclerosing cholangitis (PSC)—a rare liver disease with no approved treatments.
Learn more ⬇️
This patient-partnered project advances research in primary sclerosing cholangitis (PSC)—a rare liver disease with no approved treatments.
Learn more ⬇️
ERDERA's Joint Transnational Call 2025 results are out 🎉 18 projects have been selected representing ~€29 million in funding for preclinical research on rare disease therapies🔬
👉 Discover the selected projects and how they adress the call's core aims: https://loom.ly/BAShwKw #ERDERA #RareDisease
👉 Discover the selected projects and how they adress the call's core aims: https://loom.ly/BAShwKw #ERDERA #RareDisease
ERDERA announces first Joint Transnational Call 2025 portfolio of preclinical therapy projects for rare diseases - ERDERA
Eighteen international pre clinical therapy projects selected under ERDERA’s first Joint Transnational Call will accelerate treatment options for people living with rare diseases across Europe and beyond
erdera.org
December 17, 2025 at 6:06 PM
🎉 Congratulations to @uhn.ca’s Dr. Sonya MacParland on receiving funding through ERDERA’s Joint Transnational Call 2025!
This patient-partnered project advances research in primary sclerosing cholangitis (PSC)—a rare liver disease with no approved treatments.
Learn more ⬇️
This patient-partnered project advances research in primary sclerosing cholangitis (PSC)—a rare liver disease with no approved treatments.
Learn more ⬇️
December 17, 2025 at 4:16 PM
Ice remains one of winter’s biggest hazards.❄️ A new study from @kiteuhn.bsky.social finds that even top-rated winter boots do not fully prevent slips, highlighting the need for additional safety measures.
🔗 Read more: www.uhnresearch.ca/news/ice-win...
🔗 Read more: www.uhnresearch.ca/news/ice-win...
December 17, 2025 at 4:16 PM
Ice remains one of winter’s biggest hazards.❄️ A new study from @kiteuhn.bsky.social finds that even top-rated winter boots do not fully prevent slips, highlighting the need for additional safety measures.
🔗 Read more: www.uhnresearch.ca/news/ice-win...
🔗 Read more: www.uhnresearch.ca/news/ice-win...
December 15, 2025 at 5:19 PM
A @dkjei-uhn.bsky.social team is moving us closer to a future where blindness may not be inevitable in #RetinitisPigmentosa (RP). 👁️
In a new study, the team offer a new lab RP model and a first look at the disease’s development.
🔗 Read more: www.uhnresearch.ca/news/retinal...
In a new study, the team offer a new lab RP model and a first look at the disease’s development.
🔗 Read more: www.uhnresearch.ca/news/retinal...
December 15, 2025 at 5:19 PM
A @dkjei-uhn.bsky.social team is moving us closer to a future where blindness may not be inevitable in #RetinitisPigmentosa (RP). 👁️
In a new study, the team offer a new lab RP model and a first look at the disease’s development.
🔗 Read more: www.uhnresearch.ca/news/retinal...
In a new study, the team offer a new lab RP model and a first look at the disease’s development.
🔗 Read more: www.uhnresearch.ca/news/retinal...
December 12, 2025 at 4:51 PM
Innovation in neurovascular care!
Dr. Pascal Mosimann at @kbi-uhn.bsky.social has developed MagFlow, a microcatheter system that uses blood flow to navigate vessels 270% smaller than ever before.
This could transform treatment for #stroke, aneurysms & more.
🔗: www.uhnresearch.ca/news/microca...
Dr. Pascal Mosimann at @kbi-uhn.bsky.social has developed MagFlow, a microcatheter system that uses blood flow to navigate vessels 270% smaller than ever before.
This could transform treatment for #stroke, aneurysms & more.
🔗: www.uhnresearch.ca/news/microca...
December 12, 2025 at 4:51 PM
Innovation in neurovascular care!
Dr. Pascal Mosimann at @kbi-uhn.bsky.social has developed MagFlow, a microcatheter system that uses blood flow to navigate vessels 270% smaller than ever before.
This could transform treatment for #stroke, aneurysms & more.
🔗: www.uhnresearch.ca/news/microca...
Dr. Pascal Mosimann at @kbi-uhn.bsky.social has developed MagFlow, a microcatheter system that uses blood flow to navigate vessels 270% smaller than ever before.
This could transform treatment for #stroke, aneurysms & more.
🔗: www.uhnresearch.ca/news/microca...
New research from @kiteuhn.bsky.social explores how adapting mindfulness practices can remove barriers for individuals with spinal cord injury, supporting psychological well-being and recovery.
🔗 Read more: www.uhnresearch.ca/news/mindful...
--
@uhn.ca
🔗 Read more: www.uhnresearch.ca/news/mindful...
--
@uhn.ca
December 11, 2025 at 4:07 PM
New research from @kiteuhn.bsky.social explores how adapting mindfulness practices can remove barriers for individuals with spinal cord injury, supporting psychological well-being and recovery.
🔗 Read more: www.uhnresearch.ca/news/mindful...
--
@uhn.ca
🔗 Read more: www.uhnresearch.ca/news/mindful...
--
@uhn.ca
@bowang87.bsky.social @vectorinstitute.ai @uhnaihub.bsky.social @amia.org @uoftmedicine.bsky.social @uoftcompsci.bsky.social
December 10, 2025 at 4:16 PM
Researchers from @uhn.ca have built ECG-FM, an open-source #AI model that can deliver faster, more consistent heart screening and risk assessment by interpreting electrocardiogram data. 💓
🔗 Read more: www.uhnresearch.ca/news/harness...
🔗 Read more: www.uhnresearch.ca/news/harness...
December 10, 2025 at 4:16 PM
Researchers from @uhn.ca have built ECG-FM, an open-source #AI model that can deliver faster, more consistent heart screening and risk assessment by interpreting electrocardiogram data. 💓
🔗 Read more: www.uhnresearch.ca/news/harness...
🔗 Read more: www.uhnresearch.ca/news/harness...
UHN is proud to be ranked #1 on the list of Canada’s Top 40 Research Hospitals from Research Infosource Inc. for the 15th year in a row!
Thanks to our incredible research community for their continued dedication to #HealthDiscovery, #care & #education!
🔗: www.uhnresearch.ca/news/uhn-can...
Thanks to our incredible research community for their continued dedication to #HealthDiscovery, #care & #education!
🔗: www.uhnresearch.ca/news/uhn-can...
December 4, 2025 at 3:13 PM
UHN is proud to be ranked #1 on the list of Canada’s Top 40 Research Hospitals from Research Infosource Inc. for the 15th year in a row!
Thanks to our incredible research community for their continued dedication to #HealthDiscovery, #care & #education!
🔗: www.uhnresearch.ca/news/uhn-can...
Thanks to our incredible research community for their continued dedication to #HealthDiscovery, #care & #education!
🔗: www.uhnresearch.ca/news/uhn-can...
Congratulations to the team! 👏
December 2, 2025 at 5:03 PM
Congratulations to the team! 👏
Reposted by Research at UHN
A novel inhibitor, developed by Dr. Keith Stewart’s team at @uhn.ca's @pmresearch-uhn.bsky.social, successfully blocked cancer cell’s recycling system in multiple myeloma. It also shows promise for boosting anti-tumour immunity and for use in other blood malignancy.
doi.org/10.1182/bloo...
doi.org/10.1182/bloo...
December 2, 2025 at 4:21 PM
A novel inhibitor, developed by Dr. Keith Stewart’s team at @uhn.ca's @pmresearch-uhn.bsky.social, successfully blocked cancer cell’s recycling system in multiple myeloma. It also shows promise for boosting anti-tumour immunity and for use in other blood malignancy.
doi.org/10.1182/bloo...
doi.org/10.1182/bloo...